Mistake 3: skipping the starting dose Some people look at the 0.25mg starting dose, correctly identify that it is not a therapeutically significant dose for weight loss, and decide to start at 1.0mg or higher
Ileostomists show a significant reduction in circulating GLP-1 associated with elevated glucagon concentrations, indicating the colonic endocrine tissue to have an important role in postprandial metabolism (184)
Many people gain weight back after stopping GLP1 drugs
It runs through December 31, 2027, and requires meeting BMI-based clinical criteria
3,12,13 In addition to stimulating insulin secretion, GLP-1 inhibits glucagon secretion, and thereby decreases plasma glucose levels
These arent all the possible side effects for either drugjust the most common